Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

US Business Cycle Indicators: Industrial, Mfg. Production, Retail Sales

Nominal retail sales upside surprise (+0.2% vs consensus +0.1% m/m), but actual real declines. Manufacturing production +0.3% vs. consensus +0.2% m/m (industrial production down primarily because of utilities). Figure 1: NFP employment (bold blue), civilian employment with smoothed population controls (bold orange), industrial production (red), personal income excluding current transfers in…

US Business Cycle Indicators: Industrial, Mfg. Production, Retail Sales

The US economy showed mixed signals in its latest business cycle indicators. While nominal retail sales experienced an upside surprise in the month of October, the actual real decline was evident. Manufacturing production increased by 0.3% compared to the previous month's consensus of 0.2%, although industrial production was primarily down due to utilities.

The data, presented in Figure 1, includes various economic indicators such as employment figures, industrial production, personal income, manufacturing and trade sales, and GDP, all normalized to a base of 2025M01=0. Notably, while retail sales had an upward revision, the overall trend indicates a decrease in total and ex-gasoline station sales. The figures are presented in millions of 1982-84 dollars, as shown in Figure 3.

Written by urgent.news from Econbrowser's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at econbrowser.com →

More in Finance & Markets

Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?

Lilly's revenue growth is turbocharged by its weight-loss pipeline, while Novo's global footprint and far lower valuation raise a tougher question about risk versus reward.

  • Eli Lilly reported $86.5 billion revenue and $27.6 billion net income in 2026 fiscal year
  • Novo Nordisk had $49.0 billion revenue and $16.6 billion net income in 2026 fiscal year
  • Novo Nordisk is more affordable with lower valuation multiples than Eli Lilly

More from Tuesday 17 November →